Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.67 |
| ▸ | DPP8 | Q6V1X1 | 8/20 | 0.67 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.67 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.67 |
| ▸ | ACE | P12821 | 1/20 | 0.67 |
| ▸ | HTR2A | P28223 | 1/20 | 0.67 |
| ▸ | FAP | Q12884 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29558815 | 1.00 | DPP4 (0.67) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL3513247 | 0.90 | DPP4 (0.86) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL25840245 | 0.90 | DPP4 (0.57) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL3793968 | 0.88 | DPP4 (0.63) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL28452793 | 0.88 | DPP4 (0.63) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL3793975 | 0.88 | DPP4 (0.63) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL25304263 | 0.87 | DPP4 (0.69) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL24713208 | 0.85 | DPP4 (0.50) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL13472178 | 0.85 | DPP4 (0.51) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL4535123 | 0.85 | DPP4 (0.59) | DPP4DPP8DPP9DPP7ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 353 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078417-A1 | TRANSAMINASE BIOCATALYSTS | CODEXIS, INC. (US) | 2026-03-19 | — | — | US | claimed |
| US-20250313814-A1 | OMEGA-TRANSAMINASE MUTANT AND APPLICATION THEREOF | ZHEJIANG YONGTAI PHARMACEUTICAL CO., LTD. (CN) | 2025-10-09 | — | — | US | claimed |
| EP-4506451-A1 | OMEGA-TRANSAMINASE MUTANT AND USE THEREOF | Zhejiang Yongtai Technology Co., Ltd. (CN) | 2025-02-12 | — | — | EP | claimed |
| CN-119082067-A | Artificial transaminase for synthesis of sitagliptin | 上海邦林生物科技有限公司 | 2024-12-06 | — | — | CN | claimed |
| CN-117286130-A | Method for covalently immobilizing transaminase by using aminated carbon nano tube | 浙江工业大学 | 2023-12-26 | — | — | CN | claimed |
| CN-115873816-A | Transaminase mutant for synthesizing sitagliptin | 上海邦林生物科技有限公司 | 2023-03-31 | — | — | CN | claimed |
| US-20210332399-A1 | TRANSAMINASE BIOCATALYSTS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2021-10-28 | — | — | US | claimed |
| US-11078505-B2 | Transaminase biocatalysts | CODEXIS, INC. (US) | 2021-08-03 | — | — | US | claimed |
| CN-111518783-B | Recombinant (R) -omega-transaminase, mutant and application thereof in preparation of sitagliptin | 浙江工业大学 | 2021-07-23 | — | — | CN | claimed |
| CN-109777813-B | transaminase-PLP co-immobilized enzyme and preparation and application thereof | 浙江工业大学 | 2021-05-07 | — | — | CN | claimed |
| WO-2013065066-A1 | PROCESSES FOR PREPARING 4-OXO-4-[3-(TRIFLUOROMETHYL)-5,6- DIHYDRO [L,2,41-TRIAZOLO[43-A]PYRAZIN-7(8H)-YL]-L-(2,4,5- TRIFLUOROPHENYL)BUTAN-2-AMINE | CADILA HEALTHCARE LIMITED (IN) | 2013-05-10 | — | — | WO | claimed |
| WO-2012177527-A1 | IMMOBILIZED TRANSAMINASES AND PROCESS FOR MAKING AND USING IMMOBILIZED TRANSAMINASE | MERCK SHARP & DOHME CORP. (US) | 2012-12-27 | — | — | WO | claimed |
| US-20120329108-A1 | Transaminase Biocatalysts | CODEXIS, INC. (US) | 2012-12-27 | — | — | US | claimed |
| WO-2011142825-A2 | NOVEL SULFUR CONTAINING COMPOUNDS | DISSYMMETRIX (P) LTD. (IN) | 2011-11-17 | — | — | WO | claimed |
| EP-2331545-A2 | IMPROVED PROCESS FOR PREPARATION OF (2R)-4-OXO-4-[3- (TRIFLUOROMETHYL)-5,6-DIHYDRO [1,2,4]-TRIAZOLO[4,3-A]PYRAZIN- 7(8H)-YL]-L-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE&NEW IMPURITIES IN PREPARATION THEREOF | Cadila Healthcare Limited (IN) | 2011-06-15 | — | — | EP | claimed |
| WO-2011060213-A2 | PREPARATION OF SITAGLIPTIN AND SALTS THEREOF | DR. REDDY'S LABORATORIES LTD. (IN) | 2011-05-19 | — | — | WO | claimed |
| US-20100285541-A1 | TRANSAMINASE BIOCATALYSTS | CODEXIS, INC. (US) | 2010-11-11 | — | — | US | claimed |
| US-20100274017-A1 | PROCESSES FOR THE PREPARATION OF SITAGLIPTIN AND PHARMACEUTICLLY ACCEPTABLE SALTS THEREOF | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-10-28 | — | — | US | claimed |
| WO-2010122578-A2 | PROCESS FOR THE PREPARATION OF SITAGLIPTIN AND ITS INTERMEDIATES | MSN LABORATORIES LIMITED (IN) | 2010-10-28 | — | — | WO | claimed |
| WO-2010032264-A2 | IMPROVED PROCESS FOR PREPARATION OF (2R)-4-OXO-4-[3- (TRIFLUOROMETHYL)-5,6-DIHYDRO [1,2,4]-TRIAZOLO[4,3-A]PYRAZIN- 7(8H)-YL]-L-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE & NEW IMPURITIES IN PREPARATION THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2010-03-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100285541-A1 | TRANSAMINASE BIOCATALYSTS | GOT1, GOT2, ENPEP | DPP4 80/4885DPP8 58/4885DPP9 46/4885 |
| US-20100274017-A1 | PROCESSES FOR THE PREPARATION OF SITAGLIPTIN AND PHARMACEUTICLLY ACCEPTABLE SALTS THEREOF | DPP4, DPP9, DPP8 | DPP4 1/4885DPP8 3/4885DPP9 2/4885 |
| US-20260078417-A1 | TRANSAMINASE BIOCATALYSTS | XDH, AGXT, PEPD | DPP4 145/4885DPP8 94/4885DPP9 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.